Protalix BioTherapeutics, Inc. (PLX)
USD 2.26
(-3.63%)
USD 2.26
(-3.63%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 19.04 Million USD | 13.34% |
| 2022 | 16.8 Million USD | -6.41% |
| 2021 | 17.95 Million USD | 37.24% |
| 2020 | 13.08 Million USD | 60.42% |
| 2019 | 8.15 Million USD | -4.83% |
| 2018 | 8.56 Million USD | 9.4% |
| 2017 | 7.83 Million USD | 49.34% |
| 2016 | 5.24 Million USD | -9.05% |
| 2015 | 5.76 Million USD | -13.5% |
| 2014 | 6.66 Million USD | -16.21% |
| 2013 | 7.95 Million USD | 97.0% |
| 2012 | 4.03 Million USD | 1347.67% |
| 2011 | 279 Thousand USD | -76.53% |
| 2010 | 1.18 Million USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 22.34 Million USD | 17.33% |
| 2024 Q2 | 20.71 Million USD | -7.28% |
| 2023 Q4 | 19.04 Million USD | -11.76% |
| 2023 FY | 19.04 Million USD | 13.34% |
| 2023 Q1 | 20.3 Million USD | 20.82% |
| 2023 Q2 | 19.63 Million USD | -3.29% |
| 2023 Q3 | 21.58 Million USD | 9.92% |
| 2022 Q4 | 16.8 Million USD | 15.4% |
| 2022 Q2 | 16.5 Million USD | -0.52% |
| 2022 Q3 | 14.56 Million USD | -11.78% |
| 2022 Q1 | 16.59 Million USD | -7.57% |
| 2022 FY | 16.8 Million USD | -6.41% |
| 2021 Q3 | 14.73 Million USD | 7.99% |
| 2021 Q1 | 13.91 Million USD | 6.37% |
| 2021 FY | 17.95 Million USD | 37.24% |
| 2021 Q4 | 17.95 Million USD | 21.89% |
| 2021 Q2 | 13.64 Million USD | -1.98% |
| 2020 Q4 | 13.08 Million USD | -1.5% |
| 2020 FY | 13.08 Million USD | 60.42% |
| 2020 Q1 | 9.48 Million USD | 16.35% |
| 2020 Q2 | 11.06 Million USD | 16.62% |
| 2020 Q3 | 13.28 Million USD | 20.03% |
| 2019 Q2 | 6.99 Million USD | 4.34% |
| 2019 Q3 | 7.52 Million USD | 7.53% |
| 2019 Q4 | 8.15 Million USD | 8.37% |
| 2019 Q1 | 6.7 Million USD | -21.73% |
| 2019 FY | 8.15 Million USD | -4.83% |
| 2018 Q3 | 7.95 Million USD | 14.06% |
| 2018 FY | 8.56 Million USD | 9.4% |
| 2018 Q4 | 8.56 Million USD | 7.66% |
| 2018 Q2 | 6.97 Million USD | -0.58% |
| 2018 Q1 | 7.01 Million USD | -10.39% |
| 2017 FY | 7.83 Million USD | 49.34% |
| 2017 Q3 | 7.47 Million USD | 5.95% |
| 2017 Q1 | 7.1 Million USD | 35.37% |
| 2017 Q4 | 7.83 Million USD | 4.73% |
| 2017 Q2 | 7.05 Million USD | -0.58% |
| 2016 FY | 5.24 Million USD | -9.05% |
| 2016 Q1 | 5.73 Million USD | -0.52% |
| 2016 Q2 | 6.06 Million USD | 5.75% |
| 2016 Q3 | 4.86 Million USD | -19.89% |
| 2016 Q4 | 5.24 Million USD | 7.92% |
| 2015 Q4 | 5.76 Million USD | -9.02% |
| 2015 Q3 | 6.33 Million USD | -0.46% |
| 2015 FY | 5.76 Million USD | -13.5% |
| 2015 Q1 | 6.87 Million USD | 3.18% |
| 2015 Q2 | 6.36 Million USD | -7.43% |
| 2014 FY | 6.66 Million USD | -16.21% |
| 2014 Q1 | 6.52 Million USD | -17.97% |
| 2014 Q4 | 6.66 Million USD | -2.39% |
| 2014 Q3 | 6.83 Million USD | -4.27% |
| 2014 Q2 | 7.13 Million USD | 9.32% |
| 2013 Q4 | 7.95 Million USD | 5.02% |
| 2013 Q3 | 7.57 Million USD | 5.37% |
| 2013 Q1 | 5.77 Million USD | 42.93% |
| 2013 Q2 | 7.19 Million USD | 24.56% |
| 2013 FY | 7.95 Million USD | 97.0% |
| 2012 Q4 | 4.03 Million USD | 96.26% |
| 2012 FY | 4.03 Million USD | 1347.67% |
| 2012 Q3 | 2.05 Million USD | 100.0% |
| 2012 Q2 | 1.02 Million USD | 291.25% |
| 2012 Q1 | 263 Thousand USD | -5.73% |
| 2011 Q4 | 279 Thousand USD | -34.66% |
| 2011 FY | 279 Thousand USD | -76.53% |
| 2011 Q1 | 1.1 Million USD | -7.4% |
| 2011 Q2 | 537 Thousand USD | -51.23% |
| 2011 Q3 | 427 Thousand USD | -20.48% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q3 | 5.09 Million USD | 0.0% |
| 2010 FY | 1.18 Million USD | 0.0% |
| 2010 Q4 | 1.18 Million USD | -76.67% |
| 2010 Q1 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -1.18 Million USD | 1708.532% |
| Ampio Pharmaceuticals, Inc. | 1.00 USD | -1904499900.0% |
| Armata Pharmaceuticals, Inc. | - USD | -Infinity% |
| Actinium Pharmaceuticals, Inc. | - USD | -Infinity% |
| Azitra, Inc. | -215.21 Thousand USD | 8949.126% |
| Can-Fite BioPharma Ltd. | - USD | -Infinity% |
| Chromocell Therapeutics Corporation | - USD | -Infinity% |
| Calidi Biotherapeutics, Inc. | - USD | -Infinity% |
| CEL-SCI Corporation | 2.24 Million USD | -747.17% |
| iBio, Inc. | - USD | -Infinity% |
| Lineage Cell Therapeutics, Inc. | - USD | -Infinity% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | - USD | -Infinity% |
| Navidea Biopharmaceuticals, Inc. | 427.34 Thousand USD | -4356.597% |
| NovaBay Pharmaceuticals, Inc. | 2.87 Million USD | -561.974% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | - USD | -Infinity% |
| BiomX Inc. | - USD | -Infinity% |
| BiomX Inc. | - USD | -Infinity% |
| Palatin Technologies, Inc. | - USD | -Infinity% |
| Scorpius Holdings, Inc. | 909.15 Thousand USD | -1994.795% |
| Theriva Biologics, Inc. | - USD | -Infinity% |